Chardan Capital analyst Keay Nakae maintained a Buy rating on ContraFect (CFRX) today and set a price target of $17.50. The company’s shares closed last Monday at $6.14.
According to TipRanks.com, Nakae is a 5-star analyst with an average return of 29.5% and a 53.7% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Arrowhead Pharmaceuticals, and Lineage Cell Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ContraFect with a $14.75 average price target, which is a 132.3% upside from current levels. In a report issued on March 11, Mizuho Securities also maintained a Buy rating on the stock with a $12.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.45 and a one-year low of $4.40. Currently, ContraFect has an average volume of 623.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ContraFect Corp. is a clinical stage biotechnology company , which engages in discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases. Its pipeline consists of CF-301, a bacteriophage-derived lysin with potent activity against Staphylococcus aureus bloodstream infections; and CF-404, which composed of three fully human monoclonal antibodies designed to treat all seasonal strains of human influenza. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.
